User Fee Bill Puts Industry, FDA to Work on Supply Chain Risks
This article was originally published in The Gold Sheet
Executive Summary
The user fee legislation Congress approved June 26 makes quality risk management a GMP requirement, further pressuring pharmaceutical manufacturers to make sure they are protecting their global supply chains. The bill directs FDA to inspect based on risk rather than time or location, and to rely on trusted foreign inspectorates, while adding new user fees for generic drugs that will boost funding for further expansion of the agency’s inspectorate.
You may also be interested in...
Xavier Initiative Aims to Develop Good Supply Practices
When Xavier University convened a group of pharmaceutical manufacturing supply chain quality experts to find out why they have such problems with their suppliers, they discovered a surprising root cause: their own companies. Now they’re identifying steps the industry can take to improve the situation.
Xavier Initiative Aims to Develop Good Supply Practices
When Xavier University convened a group of pharmaceutical manufacturing supply chain quality experts to find out why they have such problems with their suppliers, they discovered a surprising root cause: their own companies. Now they’re identifying steps the industry can take to improve the situation.
FDA Import Two-fer: Consolidated Hearings Could Speed Counterfeit Destruction
Proposed rule aims to deter bad actors looking to introduce the products into the U.S. drug supply.